Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73

Cell Cycle

Volumn 15, Issue 2, 2016, Pages 164-171

  Venkatanarayan, Avinashnarayan ^a,b   Raulji, Payal ^a,b   Norton, William ^a   Flores, Elsa R ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

p53 family; targeted therapy; tumor suppressors

Indexed keywords

PRAMLINTIDE; PROTEIN P53; PROTEIN P63; PROTEIN P73; AMINOTRANSFERASE; AMYLIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; DELTA NP73 PROTEIN, HUMAN; DNA BINDING PROTEIN; GLUTAMINE-PYRUVATE AMINOTRANSFERASE; NUCLEAR PROTEIN; P73 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN; TIGAR PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN; TRP63 PROTEIN, MOUSE; TRP73 PROTEIN, MOUSE; TUMOR PROTEIN P73; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER PREVENTION; CONTROLLED STUDY; MOUSE; NONHUMAN; PROTEIN TARGETING; THYMUS LYMPHOMA; TUMOR REGRESSION; UPREGULATION; AGONISTS; ANIMAL; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLYCOLYSIS; HUMAN; KNOCKOUT MOUSE; LYMPHOMA; METABOLISM; MORTALITY; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; THYMUS NEOPLASMS;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; HYPOGLYCEMIC AGENTS; ISLET AMYLOID POLYPEPTIDE; LYMPHOMA; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; THYMUS NEOPLASMS; TRANS-ACTIVATORS; TRANSAMINASES; TUMOR PROTEIN P73; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84962868865     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1121333     Document Type: Article

References (31)

1. T.Iwakuma, G.Lozano, E.R.Flores. Li-Fraumeni syndrome: a p53 family affair. Cell Cycle 2005; 4:865-7; PMID:15917654; http://dx.doi.org/10.4161/cc.4.7.1800
2. P.A.Muller, K.H.Vousden. p53 mutations in cancer. Nat Cell Biol 2013; 15:2-8; PMID:23263379; http://dx.doi.org/10.1038/ncb2641
3. C.P.Martins, L.Brown-Swigart, G.I.Evan. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127:1323-34; PMID:17182091; http://dx.doi.org/10.1016/j.cell.2006.12.007
4. A.Ventura. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661-5; PMID:17251932; http://dx.doi.org/10.1038/nature05541
5. K.H.Khoo, C.S.Verma, D.P.Lane. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014; 13:217-36; PMID:24577402; http://dx.doi.org/10.1038/nrd4288
6. C.J.Brown, S.Lain, C.S.Verma, A.R.Fersht, D.P.Lane. Awakening guardian angels: drugging the p53 pathway. Nature Rev Cancer 2009; 9:862-73; http://dx.doi.org/10.1038/nrc2763
7. D.P.Lane. Cancer p53, guardian of the genome. Nature 1992; 358:15-6; PMID:1614522; http://dx.doi.org/10.1038/358015a0
8. C.A.Brady. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145:571-83; PMID:21565614; http://dx.doi.org/10.1016/j.cell.2011.03.035
9. D.M.Feldser, K.K.Kostova, M.M.Winslow, S.E.Taylor, C.Cashman, C.A.Whittaker, F.J.Sanchez-Rivera, R.Resnick, R.Bronson, M.T.Hemann, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010; 468:572-5; PMID:21107428; http://dx.doi.org/10.1038/nature09535
10. W.Xue. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-60; PMID:17251933; http://dx.doi.org/10.1038/nature05529
11. Y.Wang, Y.A.Suh, M.Y.Fuller, J.G.Jackson, S.Xiong, T.Terzian, A.Quintás-Cardama, J.A.Bankson, A.K.El-Naggar, G.Lozano. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 2011; 121:893-904; PMID:21285512; http://dx.doi.org/10.1172/JCI44504.
12. G.A.Lang, T.Iwakuma, Y.A.Suh, G.Liu, V.A.Rao, J.M.Parant, Y.A.Valentin-Vega, T.Terzian, L.C.Caldwell, L.C.Strong, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119:861-72; PMID:15607981; http://dx.doi.org/10.1016/j.cell.2004.11.006
13. E.R.Flores. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416:560-4; PMID:11932750; http://dx.doi.org/10.1038/416560a
14. E.R.Flores. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363-73; PMID:15837625; http://dx.doi.org/10.1016/j.ccr.2005.02.019
15. K.P.Olive, D.A.Tuveson, Z.C.Ruhe, B.Yin, N.A.Willis, R.T.Bronson, D.Crowley, T.Jacks. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119:847-60; PMID:15607980; http://dx.doi.org/10.1016/j.cell.2004.11.004
16. X.Su, D.Chakravarti, E.R.Flores. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer 2013; 13:136-43; http://dx.doi.org/10.1038/nrc3446
17. A.Yang. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8; PMID:10227294; http://dx.doi.org/10.1038/19539
18. A.Yang. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99-103; PMID:10716451; http://dx.doi.org/10.1038/35003607
19. E.Comperat. p63 gene expression study and early bladder carcinogenesis. Urology 2007; 70:459-62; PMID:17905096; http://dx.doi.org/10.1016/j.urology.2007.04.030
20. C.Di Como. J. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002; 8:494-501; PMID:11839669
21. K.Nylander. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002; 198:417-27; PMID:12434410; http://dx.doi.org/10.1002/path.1231
22. A.I.Zaika, N.Slade, S.H.Erster, C.Sansome, T.W.Joseph, M.Pearl, E.Chalas, U.M.Moll. Np73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors. J Exp Med 2002; 196:765-80; PMID:12235210; http://dx.doi.org/10.1084/jem.20020179
23. A.Venkatanarayan, P.Raulji, W.Norton, D.Chakravarti, C.Coarfa, X.Su, S.K.Sandur, M.S.Ramirez, J.Lee, C.V.Kingsley, et al. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature 2015; 517:626-30; PMID:25409149; http://dx.doi.org/10.1038/nature13910
24. A.Yang, p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305-16; PMID:9774969; http://dx.doi.org/10.1016/S1097-2765(00)80275-0
25. X.Su. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467:986-90; PMID:20962848; http://dx.doi.org/10.1038/nature09459
26. R.Tomasini. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008; 22:2677-91; PMID:18805989; http://dx.doi.org/10.1101/gad.1695308
27. S.Suzuki. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010; 107:7461-6; http://dx.doi.org/10.1073/pnas.1002459107
28. K.Bensaad. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107-20; PMID:16839880; http://dx.doi.org/10.1016/j.cell.2006.05.036
29. K.Pillay, P.Govender. Amylin uncovered: a review on the polypeptide responsible for type II diabetes. Bio Med Res Int 2013; 2013:826706; PMID:23607096; http://dx.doi.org/10.1155/2013/826706
30. S.Edelman, H.Maier, K.Wilhelm. Pramlintide in the treatment of diabetes mellitus. Bio Drugs 2008; 22:375-86; PMID:18998755; http://dx.doi.org/10.2165/0063030-200822060-00004
31. G.Christopoulos. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 1999; 56:235-42; PMID:10385705